WHO Examines Vaccine Options as Ebola Outbreak Escalates in DRC — 131 Dead, 500+ Infected

Overview : The WHO is assessing candidate vaccines and treatments to curb a rapidly spreading Ebola outbreak in the Democratic Republic of Congo (DRC). The surge has killed 131 people and infected over 500 , prompting an international health emergency declaration. Key Developments WHO representative Anne Ancia said the agency is reviewing all candidate vaccines and therapeutics. Tedros Adhanom Ghebreyesus expressed deep concern and will convene an emergency meeting on the crisis. There is no approved vaccine for the Bundibugyo strain causing the current outbreak. Existing vaccines target the Zaire strain , and pre‑qualified vaccines cannot be used now. The vaccine candidate Ervebo is under review and may become available after about two months. Important Facts This is the 17th Ebola outbreak in the DRC. The deadliest DRC outbreak (2018‑2020) claimed 2,300 lives . WHO has deployed more than 40 experts and sent 12 tonnes of supplies, including PPE , from Kinshasa and Nairobi. Collaboration with Doctors Without Borders is underway to set up treatment centres. The WHO technical advisory group will meet to prioritise vaccine candidates. UPSC Relevance Understanding the WHO’s role highlights the importance of global health governance (GS1). The distinction between virus strains (Bundibugyo vs. Zaire) illustrates challenges in vaccine development and deployment , a recurring theme in health‑policy questions. The coordination with NGOs like Doctors Without Borders underscores the need for public‑private partnerships in disaster response, relevant to GS2 (Polity) and GS4 (Ethics). The emergency meeting convened by the Director‑General reflects decision‑making mechanisms in international organisations, a typical UPSC case study. Way Forward WHO will finalise vaccine prioritisation, aim to secure Ervebo or other candidates, and expand laboratory capacity. Strengthening PPE supplies and field teams remains critical. Continuous monitoring and rapid response are essential to prevent the outbreak from extending beyond the projected two‑month window.